Celebrex (Celecoxib) Treatment of Laryngeal Papilloma
Status:
Terminated
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
Respiratory recurrent papilloma (RRP) is one of the most common benign tumors. Surgical
removal is the current management for RRP, but it is a very traumatic procedure, and often
leads to permanent voice dysfunction. In this study, we will develop a new, combined RRP
treatment with a pulsed dye laser (PDL) and Celebrex. We will determine if Celebrex, a newly
developed inhibitor of cyclooxygenase (COX)-2, can provide a long-term inhibitory effect on
RRP, therefore preventing RRP from recurring. This combined strategy, if successful in this
proposed study, will provide a new and ideal "voice-preserving" therapy for RRP that will
deliver long-term efficacy in managing RRP.
Phase:
Phase 2
Details
Lead Sponsor:
Boston University
Collaborator:
National Institute on Deafness and Other Communication Disorders (NIDCD)